Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy

Blood

Volumn 105, Issue 7, 2005, Pages 2793-2801

  Trivedi, Deepa ^b   Williams, Roxanne Y ^b   O'Reilly, Richard J ^b   Koehne, Guenther ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; PENTADECAPEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL SELECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NORMAL HUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 15944424571     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1433     Document Type: Article

References (33)

1. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immunoglobulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
2. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
3. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic transplant recipients. Blood. 1999;93:1781-1782.
4. Krause H, Hebart H, Jahn G, Mueller CA, Einsele H. Screening for CMV-specific T-cell proliferation to identify patients at risk of developing late-onset CMV disease. Bone Marrow Transplant. 1997;19:1111-1116.
5. Zaia JA, Galiez-Hawkins GM, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Inf Dis. 1997;176:782-785.
6. Quinnan GV, Kirmani N, Rook AH, et al. Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med. 1982;307:7-13.
7. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373-1380.
8. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science. 1992;257:238-241.
9. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
10. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood. 1999;94:3242-3250.
11. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
12. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood. 2001;97:994-1000.
13. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T-cells by peptide-pulsed dendritic cells. Br J Haematol. 2001;113:231-239.
14. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood drawn using dendritic cells and HLA tetramers. Blood. 2001;98:505-512.
15. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol. 1999;73:8179-8184.
16. Kern F, Faulhaber N, Froemmel C, et al. Analysis of CD8 T-cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30:1676-1682.
17. Koehne G, Smith KM, Ferguson T, et al. Quantitation, selection and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-γ production and growth of cytotoxic precursors. Blood. 2002;99:1730-1740.
18. Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood. 2000;96:109-117.
19. + T lymphocytes in IFN-γ ELISPOT assays. J Immunol Methods. 2002;259:95-110.
20. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood. 2000;96:2814-2821.
21. Busch D, Pilip I, Vijh S, Pamer EG. Coordinate regulation of complex T-cell populations responding to bacterial infection. Immunity. 1998;8:353-362.
22. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001;98:1872-1881.
23. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216.
24. Carlsson B, Cheng WS, Totterman TH, Essand M. Ex-vivo stimulation of cytomegalovirus (CMV) specific T-cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 2003;121:428-438.
25. + T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Human Immunol. 2003;64:440-452.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
27. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.
28. + T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77:5226-5240.
29. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255:27-40.
30. Khattab BA, Lindenmaier W, Frank R, Link H. Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes. J Med Virol. 1997;52:68-76.
31. Kiecker F, Streitz M, Ay B, et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose? Human Immunol. 2004;65:523-536.
32. Kozlowski S, Corr M, Shiral M, et al. Multiple pathways are involved in the extracellular processing of MHC class I restricted peptides. J Immunol. 1993;151:4033-4044.
33. Kondo E, Akatsuka Y, Kuzushima K et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004;103:630-638.